Hyloris Pharmaceuticals SA (HYL.BR)

Hyloris Pharma wins US FDA approval for pain treatment

The U.S. health regulator has approved Hyloris Pharmaceuticals' drug for post-operative pain, the Belgium-based company said on Wednesday, adding that it expects to launch the non-opioid treatment in the United States by early next year. The injectable drug, branded as Maxigesic IV, was approved as a post-operative drug in hospitals or when patients cannot take medicine orally. Maxigesic IV, a combination of paracetamol with ibuprofen solution for infusion, helps reduce pain and inflammation without the risk of opioid addiction that resulted in more than half a million deaths in the U.S. during 1999 to 2020.